China-based, CASI has signed a licensing agreement with big biotech, Spectrum Pharma's for its products: Zevalin, Marqibo and Melphalan.
CASI has been granted exclusive rights to two of Spectrum Pharmaceuticals’ commercial oncology drugs, Zevalin (ibritumomab tiuxetan) Injection for intravenous use and Marqibo (vinCRIStine sulfate LIPOSOME injection) for intravenous infusion, and a Phase 3 drug candidate, Captisol-Enabled™ Melphalan (CE melphalan), for development and commercialization in China, including Taiwan, Hong Kong and Macau.
ZEVALIN is used in the treatment of non-Hodgkin’s lymphoma (NHL).
MARQIBO is used in the treatment of acute lymphoblastic leukemia (ALL).
CE melphalan has met the endpoints in a pivotal trial for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma.
Spectrum plans to file a New Drug Application with the U.S. Food and Drug Administration (FDA) for CE melphalan in the second half of 2014.
CASI will be responsible for the development and commercialization of the three drugs, including the submission of import drug registration applications to regulatory authorities and conducting any confirmatory clinical studies in greater China, if and as required.
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Spectrum Pharmaceuticals
Report: Partnering Deals and Alliances with Big Pharma
View: Partnering Scorecard in CP Insight– view top life science partnering deals by value
View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity